Advanced search×

Small molecule inhibitors of histone acetyltransferase Tip60

Jiang Wu, Juxian Wang, Minyong Li, Yutao Yang, Binghe Wang, and Y George Zheng

Bioorg Chem 39(1):6 (2011) PMID 21186043

Tip60 is a key member of the MYST family of histone acetyltransferases and involved in a broad spectrum of cellular pathways and disease conditions. So far, small molecule inhibitors of Tip60 and other members of MYST HATs are rarely reported. To discover new small molecule inhibitors of Tip60 as mechanistic tools for functional study and as chemical leads for therapeutic development, we performed virtual screening using the crystal structure of Esa1 (the yeast homolog of Tip60) on a small molecule library database. Radioactive acetylation assays were carried out to further evaluate the virtual screen hits. Several compounds with new structural scaffolds were identified with micromolar inhibition potency for Tip60 from the biochemical studies. Further, computer modeling and kinetic assays suggest that these molecules target the acetyl-CoA binding site in Tip60. These new inhibitors provide valuable chemical hits to develop further potent inhibitors for the MYST HATs.

Copyright © 2011 Elsevier Ltd. All rights reserved.

DOI: 10.1016/j.bioorg.2010.11.003
Version: za2963e q8za8 q8zbb q8zc5 q8zda q8zed q8zff q8zga
View PDF

Similar articles you may find interesting…

  1. Volatile Substance Misuse: An Updated Review of Toxicity and Treatment.
    Jonathan B Ford, Mark E Sutter, and Timothy E Albertson

    Clin Rev Allergy Immunol (2013) PMID 23649409

    Educational campaigns and legislative actions may have led to an overall decrease in the prevalence of volatile substance misuse (VSM) in many countries; however, it is still a common practice throughout the world. Studies currently suggest that girls are misusing volatile substances...
  2. Performance of the Framingham Risk Score in Patients Receiving Hemodialysis.
    Jiun-Chi Huang, Szu-Chia Chen, and Hung-Chun Chen

    Nephrology (Carlton) (2013) PMID 23647978

    The mean follow-up period was 4.4 ± 1.5 years. Intermediate risk predicted overall hazard ratio (HR) (2.157, P = 0.039) and cardiovascular mortality (HR= 5.023; P = 0.004) versus low risk, but "high" risk did not. High risk (versus low risk) predicted cardiovascular events (HR = 2.458, P = 0.05). B...
  3. Iron metabolism and risk of cancer in the Swedish AMORIS study.
    Anjali Gaur, Helen Collins, and Mieke Van Hemelrijck

    Cancer Causes Control (2013) PMID 23649231

    As opposed to pre-clinical findings for serum iron and cancer, this population-based epidemiological study showed an inverse relation between iron metabolism and cancer risk. Minimal role of inflammatory markers observed warrants further study focusing on developments of specific cancers....